Summary
Pfizer Inc. (PFE) filed an 8-K on January 29, 2024, to furnish a press release detailing its fourth-quarter and full-year 2023 financial results, released on January 30, 2024. This filing serves as the primary communication channel for these key financial performance metrics. Investors should refer to the furnished press release (Exhibit 99) for detailed information on the company's operational and financial condition during the reported periods. While the 8-K itself does not contain the financial figures, it directs investors to the press release for comprehensive data. This includes revenue, earnings, and any forward-looking statements or guidance provided by the company. The filing reiterates that the information furnished under Item 2.02 is not considered 'filed' for the purposes of Section 18 of the Exchange Act, meaning it does not carry the same legal implications as a formally filed document.
Key Highlights
- 1Pfizer released its Q4 and Full-Year 2023 financial results via a press release on January 30, 2024.
- 2The 8-K filing on January 29, 2024, serves as notification and furnishes this press release as Exhibit 99.
- 3Investors can access detailed financial performance and operational updates within the press release.
- 4The filing incorporates the press release by reference for information on results of operations and financial condition.
- 5Information furnished under Item 2.02 is not deemed 'filed' under Section 18 of the Exchange Act, limiting legal liability for this specific disclosure.
- 6The accompanying Exhibit Index confirms the press release and a Cover Page Interactive Data File (XBRL) are part of the filing.